Expression and pharmacological evaluation of fusion protein FGF21-L-Fc / 药学学报
Acta Pharmaceutica Sinica
; (12): 787-792, 2011.
Article
em Zh
| WPRIM
| ID: wpr-233055
Biblioteca responsável:
WPRO
ABSTRACT
FGF21 (fibroblast growth factor 21) is a recently described member of the FGF family. It has been previously demonstrated that FGF21 is a potent regulator of glucose homeostasis. To improve stability of FGF21 for better efficacy, a new form of recombinant FGF21 was generated by fusion of a full length FGF21 gene and the Fc fragment of human IgG4 with flexible linker sequence. To examine the glucose regulation activity of FGF21-L-Fc, 3T3-L1 pre-adipocytes were differentiated into adipocytes, and glucose uptake activity of FGF21-L-Fc was examined by glucose oxidase and peroxidase (GOD-POD) assay. The results showed that in comparison with wild type FGF21, FGF21-L-Fc was more potent in stimulation of glucose uptake by 3T3-L1. In vivo studies on the modified protein demonstrated that FGF-L-Fc had a better efficacy in lowering blood glucose of the STZ-induced diabetic animals and controlled glucose level for a longer time. The results provided a sound basis for further studies.
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Farmacologia
/
Glicemia
/
Proteínas Recombinantes
/
Imunoglobulina G
/
Adipócitos
/
Células 3T3-L1
/
Diabetes Mellitus Experimental
/
Tratamento Farmacológico
/
Escherichia coli
/
Fatores de Crescimento de Fibroblastos
Limite:
Animals
Idioma:
Zh
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2011
Tipo de documento:
Article